272 7
Estatinas e outros antidislipidémicos
Guidelines. J Am Coll Cardiol. 2014; 63 (25 Pt B): 2889-934. Errata em: J Am Coll Cardiol.
2014; 63 (25 Pt B): 3024-5.
15. Bays HE, Jones PH, Brown WV, et al. National Lipid Association. National Lipid Association
Annual Summary of Clinical Lipidology 2015. J Clin Lipidol. 2014; 8(6 Suppl): S1-36.
16. Rosenson RS. Statins: actions, side effects, and administration. UpToDate, 2015;http://www.
uptodate.com/contents/statins-actions-side-effects-andadministration?source=search_
result&search=statins&selectedTitle=1~150
17. Rosenson RS, Brewer HB Jr. New challenges for HDL-modifying therapies as a strategy to
lower cardiovascular disease events in statin-treated patients. Cardiovasc Drugs Ther. 2015;
29: 1-3.
18. Miettinen TA, Gylling H, Nissinen MJ. The role of serum non-cholesterol sterols as surrogate
markers of absolute cholesterol synthesis and absorption. Nutr Metab Cardiovasc Dis. 2011;
21: 765-9.
19. Aguiar C. Doença Cardiovascular: Prevenir ou Tratar? Rev Port Cardiol. 2010; 29(Suppl 3):
7-17.
20. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk
curve concept. Am J Cardiol. 2006; 98: 1405-8.
21. Perk J, De Backer G, Gohlke H, et al. European Association for Cardiovascular Prevention &
Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European guidelines
on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task
Force of the European Society of Cardiology and other societies on cardiovascular disease
prevention in clinical practice. Eur Heart J. 2012; 33: 1635-701.
22. Ballantyne CM, Raichlen JS, Nicholls SJ, et al. ASTEROID Investigators. Effect of rosuvas-
tatin therapy on coronary artery stenoses assessed by quantitative coronary angiography:
a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary
atheroma burden. Circulation. 2008; 117: 2458-66.
23. Casula M, Tragni E, Catapano AL. Adherence to lipid-lowering treatment: the patient per-
spective. Patient Prefer Adherence. 2012; 6: 805-14.
24. Gylling H, Plat J, Turley S, et al. European Atherosclerosis Society Consensus Panel on Phy-
tosterols. Plant sterols and plant stanols in the management of dyslipidaemia and prevention
of cardiovascular disease. Atherosclerosis. 2014; 232: 346-60.
25. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 Diabetes. N Engl J Med.
2010; 363: 692-4.
26. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction with Aggres-
sive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early
recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized
controlled trial. JAMA. 2001; 285: 1711-18.
27. de Lemos JA, Blazing MA, Wiviott SD, et al; Investigators. Early intensive vs a delayed con-
servative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A
to Z trial. JAMA. 2004; 292: 1307-16.
